The use of experimental design in the optimization of risperidone biodegradable nanoparticles: in vitro and in vivo study
Source abstract
Abstract
The aim of this study was optimization of risperidone (model drug) biodegradable nanoparticles utilizing emulsion-solvent evaporation technique. Box-Behnken design was adopted to optimize the preparation process. Optimized nanoparticles were characterized for surface morphology using scanning electron microscope. Pharmacokinetic parameters were compared with the marketed tablets. Results revealed that the optimized formula showed 297.37 nm, 85.12%, and 59.79% for Y1, Y2, and Y3, respectively. Optimized formula showed significant improved bioavailability compared with marketed tablets. Successful achievement of prolonged risperidone release with improved bioavailability is expected to maximize patients' adherence to their antipsychotic drug therapy and to minimize risk of relapse during maintenance therapy.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Drug Solubulity and Delivery Systems · Advanced Drug Delivery Systems · Pharmaceutical studies and practices
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Pharmaceutics and Industrial Pharmacy Faculty of Pharmacy, King Abdulaziz University, Jeddah, Saudi Arabia;
Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Al-Azhar University, Cairo, Egypt;
Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Minia University, Minia, Egypt
References (28)
Show source-provided references
1. 10.1016/j.lfs.2014.06.01910.1016/j.lfs.2014.06.019 ↗
2. 10.4314/tjpr.v13i8.310.4314/tjpr.v13i8.3 ↗
3. 10.2147/DDDT.S7619410.2147/DDDT.S76194 ↗
4. 10.1002/(SICI)1097-0126(1998100)47:2<89::AID-PI86>3.0.CO;2-F10.1002/(SICI)1097-0126(1998100)47:2<89::AID-PI86>3.0.CO;2-F ↗
5. Badr-Eldin SM · Iran J Basic Med Sci. · 2013 · 16 · 1223
6. 10.1016/0378-5173(88)90073-710.1016/0378-5173(88)90073-7 ↗
7. 10.1016/j.jchromb.2007.02.00710.1016/j.jchromb.2007.02.007 ↗
8. 10.1002/jps.260055111310.1002/jps.2600551113 ↗
9. 10.1016/S0168-3659(00)00364-310.1016/S0168-3659(00)00364-3 ↗
10. Ghadi A · Caspian J Intern Med. · 2014 · 5 · 156
11. 10.1002/jps.260052121010.1002/jps.2600521210 ↗
12. 10.1038/clpt.1993.14610.1038/clpt.1993.146 ↗
13. 10.1002/1097-4636(200105)55:2<203::AID-JBM1007>3.0.CO;2-710.1002/1097-4636(200105)55:2<203::AID-JBM1007>3.0.CO;2-7 ↗
14. 10.3109/0265204900902184210.3109/02652049009021842 ↗
15. 10.1002/bmc.120410.1002/bmc.1204 ↗
16. 10.1080/026520402100002277010.1080/0265204021000022770 ↗
17. 10.1002/jps.260072102110.1002/jps.2600721021 ↗
18. 10.1016/S0927-7757(00)00825-610.1016/S0927-7757(00)00825-6 ↗
19. Marder SR · J Clin Psychiatry. · 2003 · 1 · 3
20. 10.1002/(SICI)1439-2054(20000301)276:1<1::AID-MAME1>3.0.CO;2-W10.1002/(SICI)1439-2054(20000301)276:1<1::AID-MAME1>3.0.CO;2-W ↗
21. 10.1016/S0378-5173(99)00187-810.1016/S0378-5173(99)00187-8 ↗
22. 10.2174/15672010978704830210.2174/156720109787048302 ↗
23. Peppas NA · Pharm Acta Helv. · 1985 · 60 · 110
24. 10.1016/S0378-5173(96)04697-210.1016/S0378-5173(96)04697-2 ↗
25. 10.1016/S0168-3659(96)01475-710.1016/S0168-3659(96)01475-7 ↗
26. Ritger PL · J Control Release · 1987 · 5 · 1987
27. Sussman N · Int Clin Psychopharmacol · 2002 · 17 · S29
28. 10.1002/jps.260058102110.1002/jps.2600581021 ↗